Gastrointestinal Toxicity, Systemic Inflammation, and Liver Biochemistry in Allogeneic Hematopoietic Stem Cell Transplantation Karina Jordan, Peter Pontoppidan,

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Serial Profile of Vitamins and Trace Elements during the Acute Phase of Allogeneic Stem Cell Transplantation Yasuhito Nannya, Akihito Shinohara, Motoshi.

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

How to Treat MDS without Stem Cell Transplantation

A Prospective Study of Iron Overload Management in Allogeneic Hematopoietic Cell Transplantation Survivors Navneet S. Majhail, Hillard M. Lazarus, Linda.

Kidney and Bladder Outcomes in Children with Hemorrhagic Cystitis and BK Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation Benjamin.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Allogeneic Stem Cell Transplantation in Myelofibrosis

Biopsy-Verified Bronchiolitis Obliterans and Other Noninfectious Lung Pathologies after Allogeneic Hematopoietic Stem Cell Transplantation Hilde Hylland.

Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell.

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Lung Function after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Longitudinal Study in a Population-Based Cohort Hilde Hylland Uhlving,

Access to Hematopoietic Cell Transplantation in the United States

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

Betty T. Tran, Abigail Halperin, Jason W. Chien

Caroline F. Morrison, Donna M

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest Michael Roth, Julie Krystal, Deepa Manwani, Catherine Driscoll,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model Justin N. Baker,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Alternate-Day Micafungin Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study Parinda.

Donor Selection in T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies Stefan O. Ciurea, Richard.

Paul A. Hoffmeister, Sangeeta R. Hingorani, Barry E. Storer, K

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients Pooja Khandelwal, Sabine Mellor-Heineke, Najibah.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation Eleshia J. Morrison, Shawna L. Ehlers,

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation and Its Association with a Reduction in Ploidy and an Immaturation.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation Karim E. Abou-Nassar, Haesook.

Vancomycin-Resistant Enterococcus Colonization and Bacteremia and Hematopoietic Stem Cell Transplantation Outcomes Clyde D. Ford, Michaela A. Gazdik,

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV? Marie von Lilienfeld-Toal, MD, Maria Gilleece,

Blood and Marrow Transplant Handbook

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

John Koreth, Edwin P. Alyea, William J. Murphy, Lisbeth A. Welniak

Mammen Chandy Biology of Blood and Marrow Transplantation

Praveena Narayanan, Alexandra Wolanskyj, Shawna L. Ehlers, Mark R

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.

IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation Nikhil Dole, Nathan Luebbering, Nicholas.

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Presentation transcript:

Gastrointestinal Toxicity, Systemic Inflammation, and Liver Biochemistry in Allogeneic Hematopoietic Stem Cell Transplantation Karina Jordan, Peter Pontoppidan, Hilde H. Uhlving, Katrine Kielsen, Douglas G. Burrin, Sarah Weischendorff, Ib J. Christensen, Marianne H. Jørgensen, Carsten Heilmann, Henrik Sengeløv, Klaus Müller Biology of Blood and Marrow Transplantation Volume 23, Issue 7, Pages 1170-1176 (July 2017) DOI: 10.1016/j.bbmt.2017.03.021 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Alanine aminotransferase (ALT) levels at different time points from before conditioning, during the early engraftment phase after HSCT (days 0 to 21), at 3 months (days 80 to 100) after HSCT, and 6 months (days 160 to 200) after HSCT depicted as means with 95% CI. *Indicates a statistically significant difference in levels compared to baseline at day −7 (P < .05). Biology of Blood and Marrow Transplantation 2017 23, 1170-1176DOI: (10.1016/j.bbmt.2017.03.021) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Bilirubin levels at different time points from before conditioning, during the early engraftment phase after HSCT (days 0 to 21), at 3 months (days 80 to 100) after HSCT, and 6 months (days 160 to 200) after HSCT depicted as means with 95% CI. *Indicates a statistically significant difference in levels compared to baseline day −7 (P < .05). Biology of Blood and Marrow Transplantation 2017 23, 1170-1176DOI: (10.1016/j.bbmt.2017.03.021) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Plasma citrulline levels during HSCT. Citrulline levels depicted in boxplots at 3 different time points: day −7 pre-HSCT (baseline), day +7 after HSCT, and day +21 after HSCT. During the time period the citrulline concentrations decreased from baseline and subsequently increased *P < .0001. Biology of Blood and Marrow Transplantation 2017 23, 1170-1176DOI: (10.1016/j.bbmt.2017.03.021) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions